Evaxion Biotech A/S is a biotechnology business based in the US. Evaxion Biotech A/S shares (EVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Evaxion Biotech A/S employs 35 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Evaxion Biotech A/S
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – EVAX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Evaxion Biotech A/S stock price (NASDAQ: EVAX)Use our graph to track the performance of EVAX stocks over time.
Evaxion Biotech A/S shares at a glance
|Latest market close||$7.74|
|52-week range||$5.16 - $10.34|
|50-day moving average||$8.57|
|200-day moving average||$6.97|
|Wall St. target price||$19.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.13|
Buy Evaxion Biotech A/S shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Evaxion Biotech A/S stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Evaxion Biotech A/S price performance over time
|1 week (2021-10-15)||-2.27%|
|1 month (2021-09-24)||-18.95%|
|3 months (2021-07-23)||44.67%|
|6 months (2021-04-23)||11.69%|
|1 year (2020-10-20)||N/A|
|2 years (2019-10-20)||N/A|
|3 years (2018-10-20)||N/A|
|5 years (2016-10-20)||N/A|
Evaxion Biotech A/S financials
|Gross profit TTM||$0|
|Return on assets TTM||-89.85%|
|Return on equity TTM||-183.15%|
|Market capitalisation||$148.6 million|
TTM: trailing 12 months
Shorting Evaxion Biotech A/S shares
There are currently 38,965 Evaxion Biotech A/S shares held short by investors – that's known as Evaxion Biotech A/S's "short interest". This figure is 28% down from 54,101 last month.
There are a few different ways that this level of interest in shorting Evaxion Biotech A/S shares can be evaluated.
Evaxion Biotech A/S's "short interest ratio" (SIR)
Evaxion Biotech A/S's "short interest ratio" (SIR) is the quantity of Evaxion Biotech A/S shares currently shorted divided by the average quantity of Evaxion Biotech A/S shares traded daily (recently around 205078.94736842). Evaxion Biotech A/S's SIR currently stands at 0.19. In other words for every 100,000 Evaxion Biotech A/S shares traded daily on the market, roughly 190 shares are currently held short.
To gain some more context, you can compare Evaxion Biotech A/S's short interest ratio against those of similar companies.
However Evaxion Biotech A/S's short interest can also be evaluated against the total number of Evaxion Biotech A/S shares, or, against the total number of tradable Evaxion Biotech A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evaxion Biotech A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Evaxion Biotech A/S shares in existence, roughly 0 shares are currently held short) or 0.0042% of the tradable shares (for every 100,000 tradable Evaxion Biotech A/S shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Evaxion Biotech A/S.
Find out more about how you can short Evaxion Biotech A/S stock.
Evaxion Biotech A/S share dividends
We're not expecting Evaxion Biotech A/S to pay a dividend over the next 12 months.
Evaxion Biotech A/S overview
Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark. .
Evaxion Biotech A/S in the news
Evaxion Biotech A/S : Resignation of Chief Financial Officer; Appointment of Interim Chief Financial Officer - Form 6-K
BioStock: Evaxion Biotech awarded by Frost & Sullivan for its AI platform
Evaxion Biotech A/S : Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with Its AI Immunology Platforms
Frequently asked questionsWhat percentage of Evaxion Biotech A/S is owned by institutions?
Currently 2.29% of Evaxion Biotech A/S shares are held by institutions. How many people work for Evaxion Biotech A/S?
Latest data suggests 35 work at Evaxion Biotech A/S. When does the fiscal year end for Evaxion Biotech A/S?
Evaxion Biotech A/S's fiscal year ends in December. Where is Evaxion Biotech A/S based?
Evaxion Biotech A/S's address is: Dr. Neergaards Vej 5f DK, Hoersholm, Denmark, 2970 What is Evaxion Biotech A/S's ISIN number?
Evaxion Biotech A/S's international securities identification number is: US29970R1059
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert